STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [EFFECT] Spyre Therapeutics, Inc. SEC Filing

[EFFECT] Spyre Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 4, 2026
Accession Number: 0001628280-26-012785
Submission Type: POS AM
CIK: 0001636282
Company Name: Spyre Therapeutics, Inc.
File Number: 333-285341

Source: View Original Filing on SEC EDGAR

Spyre Therapeutics

NASDAQ:SYRE

View SYRE Stock Overview →

SYRE Rankings

#1791 Ranked by Market Cap
N/A Ranked by Dividends

SYRE Latest News

Mar 6, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Feb 24, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Feb 19, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 18, 2026
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Feb 6, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

SYRE Latest SEC Filings

Mar 3, 2026
[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Mar 3, 2026
[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Mar 3, 2026
[144] Spyre Therapeutics, Inc. SEC Filing
Mar 2, 2026
[144] Spyre Therapeutics, Inc. SEC Filing
Mar 2, 2026
[EFFECT] Spyre Therapeutics, Inc. SEC Filing

SYRE Stock Data

3.19B
70.09M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM